Printer Friendly

MARION MERRELL DOW AND KODAMA LAUNCH COLLABORATION FOR JAPANESE MARKET

 KANSAS CITY, Mo./TOKYO, Feb. 25 /PRNewswire/ -- Marion Merrell Dow Inc. (NYSE: MKC), a global pharmaceutical company, and Kodama Ltd., a Japanese pharmaceutical company, today announced a marketing and new product development collaboration in Japan, the world's second-largest pharmaceutical market. Marion Merrell Dow's subsidiary in Japan, Marion Merrell Dow K.K., has agreed to purchase approximately 20 percent of Kodama's shares.
 "This strategic agreement extends Marion Merrell Dow's presence in the Japanese market, which we currently serve through Marion Merrell Dow K.K.," said Fred W. Lyons, Jr., president and chief executive officer of Marion Merrell Dow. "Kodama is a successful company with good management and a sales organization of more than 250 associates. We have worked with Kodama for years, and both organizations will grow stronger through this collaboration."
 "We are pleased to enter this collaboration, which we believe will enhance the sales of current and future products for Kodama and Marion Merrell Dow K.K.," said Tsuneo Yumikura, president of Kodama. "We are confident that expanding our longstanding relationship will benefit the medical community and patients we serve in Japan, as well as shareholders and employees of both companies."
 Current Marion Merrell Dow products in Japan include Triludan(R) (terfenadine, a nonsedating antihistamine known as Seldane(R) in the United States) and several other prescription drugs. Current Kodama products include Pollakisu(R) (oxybutynin chloride, a treatment for incontinence licensed from Marion Merrell Dow) and more than 20 other products.
 "The collaboration will enable the Marion Merrell Dow K.K. and Kodama sales forces to detail each other's products, adding to the marketing capabilities that support both companies' products," said Michael V. Aylott, Ph.D., president and chief executive officer of Marion Merrell Dow K.K. "In addition, we plan to work together on clinical development of new products." Financial terms were not disclosed.
 Potential new products under development in Japan by Marion Merrell Dow include its Nicorette(R) and Nicoderm(R) smoking cessation aids; Targocid(R) antibiotic; Sabril(R) antiepileptic; deflazacort, a bone- sparing anti-inflammatory; and dolasetron, an antiemetic.
 Kodama is headquartered in Tokyo and employs more than 550 people, including more than 250 associates in its sales organization and more than 60 Research and Development associates.
 Marion Merrell Dow K.K. employees more than 800 people, including nearly 400 sales representatives and more than 100 R&D associates. Its primary locations are in Tokyo, Osaka and Hirakata.
 Marion Merrell Dow is a research-based global pharmaceutical organization dedicated to improving the longevity and quality of human life. The company is involved in the discovery, development, manufacture and sale of pharmaceutical products worldwide. In 1992, Marion Merrell Dow had sales of $3.3 billion and invested $465 million in Research and Development.
 -0- 2/25/93
 /CONTACT: David M. Thompson or Richard M. Johnson of Marion Merrell Dow, 816-966-4000/
 (MKC)


CO: Marion Merrell Dow Inc.; Kodama Ltd.; Marion Merrell Dow K.K. ST: Missouri IN: MTC SU:

MC -- DV004 -- 0640 02/25/93 18:33 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 25, 1993
Words:497
Previous Article:WEITEK: POWER 9000 USER-INTERFACE PROCESSOR CRUSHES COMPETITORS; PC MAGAZINE EDITOR'S CHOICE AWARD WINNER DROPS S3 IN FAVOR OF WEITEK
Next Article:NEW YORK STOCK EXCHANGE CLOSING, THURSDAY, FEB. 25 /PRN/
Topics:


Related Articles
IMMULOGIC AND MARION MERRELL DOW SIGN COLLABORATION AGREEMENT TO COMMERCIALIZE IMMULOGIC'S ALLERVAX ALLERGY PRODUCTS
MARION MERRELL DOW STATEMENT ON U.S. BIOSCIENCE
MARION MERRELL DOW COMMITS TO MAJOR EXPANSION OF AFFYMAX ALLIANCE
SCIOS NOVA INC. RAISES $7.95 MILLION THROUGH EXERCISE OF WARRANTS
MARION MERRELL DOW INC. AND MITSUBISHI KASEI CORP. ANNOUNCE NORTH AMERICAN COLLABORATION
MARION MERRELL DOW K.K. INCREASES OWNERSHIP IN KODAMA
MARION MERRELL DOW INC. INCREASES ITS OWNERSHIP IN JAPAN'S KODAMA LTD.
MARION MERRELL DOW INC. ANNOUNCES 1994 FIRST QUARTER SALES AND EARNINGS
MARION MERRELL DOW INC. ANNOUNCES SECOND QUARTER 1994 EARNINGS
MARION MERRELL DOW INC. REPORTS SALES, EARNINGS FOR THIRD QUARTER AND NINE-MONTH PERIOD

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters